

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 2825.2004-001		APPLICATION NO. 09/735,273		
<div style="position: absolute; left: -100px; top: 50px; border: 1px solid black; border-radius: 50%; padding: 5px; transform: rotate(-45deg); font-weight: bold;"> OIP JUL 07 2003 </div> SUPPLEMENTAL INFORMATION DISCLOSURE PARTITION IN AN APPLICATION November 15, 2001 (Use several sheets if necessary)		APPLICANTS Edwin A. Clark, et al.		COPY		
		FILING DATE December 11, 2000		GROUP 1614		
U.S. PATENT DOCUMENTS						
EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
J	AA 5,019,646	05/28/91	Furcht et al.	530	326	
J	AB 5,922,676	07/13/99	Pasqualini et al.	514	12	
J	AC 5,633,161	05/27/97	Shyjan	435	325	
J	AD 5,674,739	10/07/97	Shyjan	435	252.3	
J	AE 6,025,137	02/15/00	Shyjan	435	6	
J	AF 4,839,464	06/13/89	McCarthy et al.	530	326	
J	AG 5,171,271	12/15/92	Furcht et al.	623	11	
J	AH 5,294,551	03/15/94	Furcht et al.	435	240. 243	
J	AI 5,116,368	05/26/92	McCarthy et al.	623	2	
J	AJ 5,147,797	09/15/92	McCarthy et al.	435	240.1	
J	AK 6,274,704 B1	08/14/01	Fukai et al.	530	326	
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
J	AL WO 96/30389	03 OC 1996	PCT			
J	AM WO 99/47671	23 SE 1999	PCT			
J	AN EP 0 837 074 A2	22 AP 1998	EPO			
J	AO JP 06-298797	25 OC 1994	JP			
J	AP JP 06-239885	30 AU 1994	JP			
J	AQ JP 04-164095	09 JU 1992	JP			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
J	AU3	Hashimoto, Y., et al., "Identification of Genes Differentially Expressed in Association with Metastatic Potential of K-1735 Murine Melanoma by Messenger RNA Differential Display," Cancer Research, 36:5266-5271 (1996).				
J	AV3	Zendman, A.J.W., et al., "TM7XN1, A Novel Human EGF-TM7-like cDNA, Detected with mRNA Differential Display Using Human Melanoma Cell Lines with Different Metastatic Potential," FEBS Letters, 446:292-298 (1999).				
J	AW3	van Groningen, J.J.M., et al., "Identification of Melanoma Inhibitory Activity and Other Differentially Expressed Messenger RNAs in Human Melanoma Cell Lines with Different Metastatic Capacity by Messenger RNA Differential Display," Cancer Research, 55:6237-6243 (1995).				
EXAMINER J. Smith			DATE CONSIDERED 11/5/03			

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
2825.2004-001APPLICATION NO.
09/735,273INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

June 13, 2001

(Use several sheets if necessary)

APPLICANTS
Edwin A. Clark, et al.FILING DATE
December 11, 2000

GROUP

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AV2	Lauffenburger, D.A., et al., Cell Migration: A Physically Integrated Molecular Process. Cell 84: 359-369 (1996).
AV2	Maniotis, A.J., et al., Vascular Channel Formation by Human Melanoma Cells in vivo and in vitro: Vasculogenic Mimicry. Am. J. Pathol. 155: 739-752 (1999).
AW2	Quilliam, L.A., et al., Guanine Nucleotide Exchange Factors: Activators of the Ras Superfamily of Proteins. BioEssays 17: 395-404 (1995).
AX2	Suwa, H., et al., Overexpression of the rhoC Gene Correlates with Progression of Ductal Adenocarcinoma of the Pancreas. Br. J. Cancer 77: 147-152 (1998).
AY2	Van Aelst, L., et al., Rho GTPases and Signaling Networks. Genes Dev. 11: 2295-2322 (1997).
AZ2	Vermeulen, S.J., et al., Transition from the Noninvasive to the Invasive Phenotype and Loss of α -Catenin in Human Colon Cancer Cells. Cancer Res. 55: 4722-4728 (1995).
AR3	Welch, D.R., et al., Microcell-mediated Transfer of Chromosome 6 into Metastatic Human C8161 Melanoma Cells Suppresses Metastasis but does not Inhibit Tumorigenicity. Oncogene 9: 255-262 (1994).
AS3	Wettersman, M.A.J., et al., Thymosin β -10 Expression in Melanoma Cell Lines and Melanocytic Lesions: A New Progression Marker for Human Cutaneous Melanoma. Int. J. Cancer 53: 278-284 (1993).
AT3	Zhang, L., et al., Gene Expression Profiles in Normal and Cancer Cells. Science 276: 1268-1272 (1997).

EXAMINER

DATE CONSIDERED

11/5/03

Duplicate
Previously
8/3/01
12/02Duplicate
Previously
8/3/01

PIPE
JUL 07 2003
OFFICE
PATENT & TRADEMARK

PTO-1449 REPRODUCED SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION November 15, 2001 (Use several sheets if necessary)		ATTORNEY DOCKET NO. 2825.2004-001		APPLICATION NO. 09/735,273	
		APPLICANTS Edwin A. Clark, et al.			
		FILING DATE December 11, 2000		GROUP 1614	

U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	

FOREIGN PATENT DOCUMENTS							
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
AX3	Zhang, M., et al., "Expression Genetics: A Different Approach to Cancer Diagnosis and Prognosis," Tibtech, 16:66-71 (1998).
AY3	Ichiro, A., "Peptide Derivative and its Use, Patent Abstracts of Japan, JP 06298797 (25 October 1994).
AZ3	Ichiro, A., "Peptide Derivative and its Use, Patent Abstracts of Japan, JP 06239885 (30 August 1994).
AR4	Hideto, M., "Peptide Derivative," Patent Abstracts of Japan, JP 04164095 (09 June 1992).

EXAMINER 	DATE CONSIDERED 11/5/03
--------------	----------------------------